RANI Arquivamentos da SEC - Rani Therapeutics Holdings, Inc.- Relatório Anual, Declaração de Procuração, Prospecto

Estatísticas Básicas

CIK

1856725

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Rani Therapeutics Holdings, Inc.

SEC Filings (Chronological Order)

Esta página fornece uma lista completa e cronológica de Arquivamentos da SEC, excluindo os arquivamentos de propriedade que fornecemos em outro lugar.

May 29, 2026	8-K	FORM 8-K Item 5.07 Submission of Matters to a Vote of Security Holders. 2. The Company’s stockholders ratified the appointment of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2026 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Comm
May 27, 2026	EX-4.1	PRE-FUNDED COMMON STOCK PURCHASE WARRANT RANI THERAPEUTICS HOLDINGS, INC. Warrant Shares: [_______] Original Issue Date: May 27, 2026 EX-4.1 Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT RANI THERAPEUTICS HOLDINGS, INC. Warrant Shares: [] Original Issue Date: May 27, 2026 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any tim
May 27, 2026	424B5	12,476,637 Shares of Class A Common Stock Pre-Funded Warrants to Purchase 6,214,953 Shares of Class A Common Stock 424B5 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-289424 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 14, 2025) 12,476,637 Shares of Class A Common Stock Pre-Funded Warrants to Purchase 6,214,953 Shares of Class A Common Stock We are offering shares of our Class A common stock, par value $0.0001 per share at the offering price of $1.07 per share of Class A commo
May 27, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2026 Rani Therapeutics Ho UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2026 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Comm
May 27, 2026	EX-10.1	SECURITIES PURCHASE AGREEMENT EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 26, 2026, by and between Rani Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to t
May 15, 2026	EX-99.1	Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition - Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill® for the treatment of obesity in collaboration with ProGen Exhibit 99.1 Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition - Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill® for the treatment of obesity in collaboration with ProGen – Appointed Alireza Javadi, Ph.D. as Chief Technical Officer - Appointed Jesper Høiland as Head of Strategy and Dr. Sara Kenkare-Mitra a
May 15, 2026	8-K	FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2026 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Comm
May 15, 2026	EX-10.1	RANI THERAPEUTICS HOLDINGS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (AS AMENDED EFFECTIVE MARCH 18, 2026) Exhibit 10.1 RANI THERAPEUTICS HOLDINGS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (AS AMENDED EFFECTIVE MARCH 18, 2026) Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Rani Therapeutics Holdings, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in t
May 15, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC.
May 15, 2026	EX-10.2	FIRST AMENDMENT TO COLLABORATION AGREEMENT Exhibit 10.2 FIRST AMENDMENT TO COLLABORATION AGREEMENT This First Amendment to the Collaboration Agreement (this "First Amendment") is entered into as of January 13, 2026 by and between Rani Therapeutics, LLC, a California limited liability company ("Rani"), and ProGen Co., Ltd. ("ProGen"). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Agreement. Re
April 16, 2026	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidenti
April 16, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi
April 16, 2026	ARS	ARS $0.2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI TH
March 26, 2026	EX-FILING FEES	CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Rani Therapeutics Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Rani Therapeutics Holdings, Inc.
March 26, 2026	EX-99.1	Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update - Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million ov Exhibit 99.1 Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update - Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Special Situations Funds, and Inv
March 26, 2026	EX-10.12	NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Exhibit 10.12 NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Rani Therapeutics Holdings, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy for his or her Board ser
March 26, 2026	EX-21.1	List of subsidiaries of Rani Therapeutics Holdings, Inc. Exhibit 21.1 List of subsidiaries of Rani Therapeutics Holdings, Inc. Name of Subsidiary Jurisdiction of Organization Rani Therapeutics, LLC California, United States of America
March 26, 2026	EX-4.2	Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities and Exchange Act of 1934 Exhibit 4.2 Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities and Exchange Act of 1934 The following is a description of the Class A common stock, par value $0.0001 per share (the “Class A common stock”) of Rani Therapeutics Holdings, Inc. (“Rani”, the “Company”, “we”, “our” or “us”) which is our only class of security registered under Section 12 of the Sec
March 26, 2026	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2026 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Co
March 26, 2026	S-8	As filed with the U.S. Securities and Exchange Commission on March 26, 2026 As filed with the U.S. Securities and Exchange Commission on March 26, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 86-3114789 (State or other jurisdiction of incorporation or organiza
March 26, 2026	EX-10.27	FORM OF KEY EMPLOYEE RETENTION AGREEMENT Exhibit 10.27 FORM OF KEY EMPLOYEE RETENTION AGREEMENT This Key Employee Retention Agreement (“Agreement”) is entered into between the undersigned individual (“Employee”) and Rani Therapeutics, LLC (“Company”). Employee is only eligible to receive the consideration set forth in this Agreement if Employee signs this Agreement within five (5) calendar days after the date Employee receives this Agree
March 26, 2026	EX-19.1	Introduction Insider Trading Policy Stock Trading by Directors, Employees and Consultants Duration Of Policy’s Applicability Penalties EXHIBIT A Frequently Asked Questions INSIDER TRADING POLICY Introduction This policy determines acceptable transactions in the securities of Rani Therapeutics Holdings, Inc.
March 26, 2026	10-K	PART I The Market and Our Strategy Our Platform Technology Our Regulatory Pathways License and Evaluation Agreements Manufacturing and Quality Assurance Commercialization Intellectual Property Government Regulation $0.2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAP
March 26, 2026	EX-10.4	RANI THERAPEUTICS, LLC SIXTH AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT Dated as of December 31, 2025 Exhibit 10.4 RANI THERAPEUTICS, LLC SIXTH AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT Dated as of December 31, 2025 THE UNITS REPRESENTED BY THIS SIXTH AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER ANY OTHER APPLICABLE SECURITIES LAWS. SUCH UNITS MAY NOT BE SOLD, ASSIGNED, PLEDGED
January 2, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2025 RANI THERAPEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2025 RANI THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or Other Jurisdiction of Incorporation)
January 2, 2026	EX-3.2	AMENDED AND RESTATED BYLAWS RANI THERAPEUTICS HOLDINGS, INC. (A DELAWARE CORPORATION) Table of Contents Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF RANI THERAPEUTICS HOLDINGS, INC. (A DELAWARE CORPORATION) Table of Contents Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS’ MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meeting 1 Section 6. Special Meetings 4 Section 7
January 2, 2026	EX-3.1	AMENDED AND RESTATED CERTIFICATE OF INCORPORATION RANI THERAPEUTICS HOLDINGS, INC. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RANI THERAPEUTICS HOLDINGS, INC. Rani Therapeutics Holdings, Inc., a Delaware corporation, hereby certifies that: ONE: The name of this corporation is Rani Therapeutics Holdings, Inc. This corporation filed its original Certificate of Incorporation with the Secretary of State of the State of Delaware on April 6, 2021. TWO: The
December 5, 2025	DEF 14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 DEF 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement Rani Therapeutics Holdings,
December 3, 2025	424B5	Up to 42,633,337 shares of Class A Common Stock Up to 125,000,004 Shares of Class A Common Stock Issuable Upon Exercise of Common Stock Warrants Up to 82,366,667 Shares of Class A Common Stock Issuable Upon Exercise of Pre-Funded Warrants 424B5 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-291394 PROSPECTUS Up to 42,633,337 shares of Class A Common Stock Up to 125,000,004 Shares of Class A Common Stock Issuable Upon Exercise of Common Stock Warrants Up to 82,366,667 Shares of Class A Common Stock Issuable Upon Exercise of Pre-Funded Warrants This prospectus relates to the proposed resale from time to ti
December 1, 2025	CORRESP	RANI THERAPEUTICS HOLDINGS, INC. 2051 Ringwood Avenue San Jose, California 95131 CORRESP RANI THERAPEUTICS HOLDINGS, INC. 2051 Ringwood Avenue San Jose, California 95131 December 1, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 RE: Rani Therapeutics Holdings, Inc. Registration Statement on Form S-3 File No. 333-291394 Ladies and Gentlemen: Rani Therapeutics Holdings, Inc. (the “Regi
November 25, 2025	PRE 14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 PRE 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement Rani Therapeutics Holdings,
November 7, 2025	S-3	As filed with the Securities and Exchange Commission on November 7, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on November 7, 2025 Registration No.
November 7, 2025	EX-FILING FEES	Security Type Calculation of Filing Fee Tables S-3 Rani Therapeutics Holdings, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Fo
November 6, 2025	EX-10.1	Collaboration and License Agreement by and between Rani Therapeutics Holdings, Inc. and Chugai Pharmaceutical Co., Ltd. dated October 16, 2025.+ Portions of this exhibit have been omitted as the Registrant has determined that (i) the omitted information is not material and (ii) the omitted material is of the type that the Registrant treats as private or confidential.
November 6, 2025	EX-99.1	Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update - Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics - - Completed $60.3 million oversubscribed pr Exhibit 99.1 Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update - Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics - - Completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Anomaly, Special Situations Funds, and Invus – –
November 6, 2025	EX-10.2	Therapeutics Holdings, Inc., Rani Management Services, Inc., and Avenue Venture Opportunities Fund, L.P., dated September 30, 2025. Exhibit 10.2 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT AND SUPPLEMENT This First Amendment to Loan and Security Agreement and Supplement (this “Amendment”) is dated as of September 30, 2025 (the “First Amendment Date”), and is entered into by and among Rani Therapeutics, LLC, a California limited liability company (“Borrower”), Rani Therapeutics Holdings, Inc., a Delaware corporation (“Parent
November 6, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC.
November 6, 2025	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 06, 2025 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation)
October 27, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2025 RANI THERAPEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2025 RANI THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or Other Jurisdiction of Incorporation) (
October 17, 2025	EX-10.3	COMMON STOCK PURCHASE WARRANT RANI THERAPEUTICS HOLDINGS, INC. Warrant Shares: [_______] Original Issue Date: [_______], 2025 EX-10.3 Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIV
October 17, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2025 RANI THERAPEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2025 RANI THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or Other Jurisdiction of Incorporation) (
October 17, 2025	EX-10.1	SECURITIES PURCHASE AGREEMENT EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 16, 2025, by and between Rani Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject
October 17, 2025	EX-10.4	PRE-FUNDED COMMON STOCK PURCHASE WARRANT RANI THERAPEUTICS HOLDINGS, INC. Warrant Shares: [_______] Original Issue Date: [ ], 2025 EX-10.4 Exhibit 10.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIV
October 17, 2025	EX-10.2	REGISTRATION RIGHTS AGREEMENT EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of October 16, 2025, between Rani Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the
August 12, 2025	CORRESP	RANI THERAPEUTICS HOLDINGS, INC. 2051 Ringwood Avenue San Jose, California 95131 CORRESP RANI THERAPEUTICS HOLDINGS, INC. 2051 Ringwood Avenue San Jose, California 95131 August 12, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Chris Edwards Re: Rani Therapeutics Holdings, Inc. Registration Statement on Form S-3 File No. 333-289424 Acceleration Request Requested Date: August 14, 2025 Reques
August 12, 2025	LETTER	LETTER August 12, 2025 Talat Imran Chief Executive Officer Rani Therapeutics Holdings, Inc.
August 8, 2025	S-3	As filed with the U.S. Securities and Exchange Commission on August 8, 2025 S-3 Table of Contents As filed with the U.S. Securities and Exchange Commission on August 8, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RANI THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 86-3114789 (State or other jurisdiction o
August 8, 2025	EX-FILING FEES	Security Type Calculation of Filing Fee Tables S-3 Rani Therapeutics Holdings, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Fo
August 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC.
August 7, 2025	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2025 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (C
August 7, 2025	EX-99.1	Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update – Announced strategic research collaboration with Chugai for two undisclosed molecules – – Presented preclinical data demonstrating bioequivalence of novel, bi Exhibit 99.1 Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update – Announced strategic research collaboration with Chugai for two undisclosed molecules – – Presented preclinical data demonstrating bioequivalence of novel, bispecific GLP-1/GLP-2 receptor agonist delivered orally via RaniPill (RT-114) compared to subcutaneous delivery at ENDO 2025 – – Phase 1 s
July 16, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2025 Rani Therapeutics H UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2025 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Com
July 16, 2025	EX-4.1	Form of Pre-Funded Warrant EX-4.1 Exhibit 4.1 PREFUNDED COMMON STOCK PURCHASE WARRANT RANI THERAPEUTICS HOLDINGS, INC. Warrant Shares: Issuance Date: July , 2025 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after t
July 16, 2025	EX-10.1	Form of Securities Purchase Agreement, dated July 14, 2025 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 14, 2025, between Rani Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and co
July 16, 2025	424B5	4,354,000 Shares of Class A Common Stock Pre-Funded Warrants to Purchase 3,146,000 Shares of Class A Common Stock 424B5 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-266444 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 10, 2022) 4,354,000 Shares of Class A Common Stock Pre-Funded Warrants to Purchase 3,146,000 Shares of Class A Common Stock We are offering 4,354,000 shares of our Class A common stock, par value $0.0001 per share at the offering price of $0.40 per share of Clas
July 11, 2025	424B5	Up to 13,160,172 Shares of Class A Common Stock Issuable Upon Exercise of Warrant 424B5 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-288509 PROSPECTUS Up to 13,160,172 Shares of Class A Common Stock Issuable Upon Exercise of Warrant This prospectus relates to the proposed resale from time to time by the selling stockholder of up to 13,160,172 shares of Class A common stock issuable upon exercise of a Series D common stock warrant. In May 2025, we i
July 10, 2025	DEF 14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 DEF 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement Rani Therapeutics Holdings,
July 9, 2025	CORRESP	July 9, 2025 CORRESP July 9, 2025 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
July 8, 2025	LETTER	LETTER July 8, 2025 Talat Imran Chief Executive Officer Rani Therapeutics Holdings, Inc. 2051 Ringwood Avenue San Jose, CA 95131 Re: Rani Therapeutics Holdings, Inc. Registration Statement on Form S-3 Filed July 3, 2025 File No. 333-288509 Dear Talat Imran: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests
July 3, 2025	EX-FILING FEES	Filing Fee Table EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Rani Therapeutics Holdings, Inc.
July 3, 2025	S-3	As filed with the Securities and Exchange Commission on July 3, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on July 3, 2025 Registration No.
June 30, 2025	PRE 14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 PRE 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement Rani Therapeutics Holdings,
June 26, 2025	8-K	FORM 8-K Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2025 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Com
May 29, 2025	8-K	FORM 8-K Item 5.07 Submission of Matters to a Vote of Security Holders. 2. The Company’s stockholders ratified the appointment of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2025 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Comm
May 20, 2025	EX-10.2	Form of Series D Common Stock Warrant Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
May 20, 2025	EX-10.1	Letter Agreement, dated May 20, 2025, by and between Rani Therapeutics Holdings, Inc. and the Investor. Exhibit 10.1 RANI THERAPEUTICS HOLDINGS, INC. May 20, 2025 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Rani Therapeutics Holdings, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you”, or similar terminology) (i) the opportunity to receive new warrants to purchase shares of the Company’s Class A common stock, par
May 20, 2025	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Comm
May 19, 2025	424B5	$16,500,000 Class A Common Stock 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-266444 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 10, 2022) $16,500,000 Class A Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated August 10, 2022 (the “Base Prospectus”), as supplemented by our prospectus supplement dated August 25, 2022 (the “Prior Prospectus Supplement” and, t
May 13, 2025	EX-99.1	Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update - Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill® Exhibit 99.1 Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update - Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - - Phase 1 study for RT-114 for the treatment of obesity expected to initiate in mid-2
May 13, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Comm
May 13, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC.
May 6, 2025	8-K	FORM 8-K Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 01, 2025 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Comm
April 30, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
April 30, 2025	8-K	FORM 8-K Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Co
April 16, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidentia
April 16, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi
April 16, 2025	ARS	ARS 81,7('67$7(6 6(&85,7,(6$1'(;&+$1(&200,66,21 :$6+,1721'& )250.
April 9, 2025	EX-16.1	Letter of Marcum LLP to the Securities and Exchange Commission dated April 8, 2025 Exhibit 16.1 April 8, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Rani Therapeutics Holdings, Inc. under Item 4.01 of its Form 8-K dated April 7, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Rani Therapeutics Holdi
April 9, 2025	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 07, 2025 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Co
March 31, 2025	S-8	As filed with the U.S. Securities and Exchange Commission on March 31, 2025 As filed with the U.S. Securities and Exchange Commission on March 31, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 86-3114789 (State or other jurisdiction of incorporation or organiza
March 31, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Co
March 31, 2025	EX-99.1	Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update - Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® c Exhibit 99.1 Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update - Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - - Announced preclinical data demonstrating successful oral delivery of semaglutide via
March 31, 2025	EX-FILING FEES	Filing Fee Table CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Rani Therapeutics Holdings, Inc.
March 31, 2025	EX-21.1	Subsidiaries of the Registrant. Exhibit 21.1 List of subsidiaries of Rani Therapeutics Holdings, Inc. Name of Subsidiary Jurisdiction of Organization Rani Therapeutics, LLC California, United States of America
March 31, 2025	EX-97.1	Policy Relating to Recovery of Erroneously Awarded Compensation Rani Therapeutics Holdings, Inc. Incentive Compensation Recoupment Policy 1. Introduction The Board of Directors (the “Board”) of Rani Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment of
March 31, 2025	EX-19.1	Insider Trading Policy. INSIDER TRADING POLICY Introduction This policy determines acceptable transactions in the securities of Rani Therapeutics Holdings, Inc.
March 31, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC.
November 14, 2024	EX-10.1	Amendment to Securities Purchase Agreement and Series B Common Stock Purchase Warrant dated September 23, 2024 between Rani Therapeutics Holdings, Inc. and the investors specified therein. Exhibit 10.1 AMENDMENT TO SECURITIES PURCHASE AGREEMENT AND SERIES B COMMON STOCK PURCHASE WARRANT This Amendment to Securities Purchase Agreement and Series B Common Stock Purchase Warrant (the “Amendment”) is entered into by and between (the “Holder”) and Rani Therapeutics Holdings, Inc. (the “Company”), effective as of July 23, 2024 (“Amendment Effective Date”). Whereas, Company issued to Holde
November 14, 2024	EX-99.1	Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update - Completed two equity offerings with total gross proceeds of approximately $20.0 million; cash runway extended into 3Q 2025 - - Announced new preclinical pharm Exhibit 99.1 Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update - Completed two equity offerings with total gross proceeds of approximately $20.0 million; cash runway extended into 3Q 2025 - - Announced new preclinical pharmacokinetic data supporting transenteric delivery of GLP-1 incretin triagonist - - Phase 1 study for RT-114, an oral GLP-1/GLP-2 dual agon
November 14, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation)
November 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC.
November 14, 2024	SC 13G	RANI / Rani Therapeutics Holdings, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-rani093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Rani Therapeutics Holdings, Inc. (Name of Issuer) Class A common stock, par value $0.0001 per share (Title of Class of Securities) 753018100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Sta
October 17, 2024	EX-99.1	Exhibit 99.1 — Joint Filing Agreement, dated October 17, 2024. EX-99.1 2 tm2426414d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 SCHEDULE 13D JOINT FILING AGREEMENT In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13D to which this Joint Filing Agreement is attached and have duly executed this Join
October 17, 2024	SC 13D/A	RANI / Rani Therapeutics Holdings, Inc. / South Lake One, Llc - SC 13D/A Activist Investment SC 13D/A 1 tm2426414d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Rani Therapeutics Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 753018 100 (CUSIP Number) Luis Felipe Correa González South Lake One LLC Avenid
October 16, 2024	EX-10.1	Form of Securities Purchase Agreement, dated October 15, 2024 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 15, 2024, between Rani Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and
October 16, 2024	424B5	3,000,000 Shares of Class A Common Stock Pre-Funded Warrants to Purchase 333,333 Shares of Class A Common Stock Series C Common Warrants to Purchase 3,333,333 Shares of Class A Common Stock 424B5 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-266444 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 10, 2022) 3,000,000 Shares of Class A Common Stock Pre-Funded Warrants to Purchase 333,333 Shares of Class A Common Stock Series C Common Warrants to Purchase 3,333,333 Shares of Class A Common Stock We are offering 3,000,000 shares of our Class A common stock ,
October 16, 2024	EX-4.2	Form of Pre-funded Warrant Exhibit 4.2 PREFUNDED COMMON STOCK PURCHASE WARRANT RANI THERAPEUTICS HOLDINGS, INC. Warrant Shares: Issuance Date: October , 2024 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the d
October 16, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2024 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (
October 16, 2024	EX-4.1	Form of Series C Common Warrant Exhibit 4.1 SERIES C COMMON STOCK PURCHASE WARRANT RANI THERAPEUTICS HOLDINGS, INC. Warrant Shares: Issuance Date: October , 2024 THIS SERIES C COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the da
September 11, 2024	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation)
September 11, 2024	EX-16.1	Letter of Ernst & Young LLP to the Securities and Exchange Commission dated September 11, 2024 Exhibit 16.1 September 11, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K dated September 11, 2024, of Rani Therapeutics Holdings, Inc. and are in agreement with the statements contained in paragraphs one through four therein under (a) Dismissal of Independent Registered Public Accounting Firm. We have no basis to a
August 6, 2024	EX-10.1	Collaboration Agreement between Rani Therapeutics, LLC and ProGen Co., Ltd. dated June 17, 2024. Exhibit 10.1 Portions of this exhibit have been omitted as the Registrant has determined that (i) the omitted information is not material and (ii) the omitted material is of the type that the Registrant treats as private or confidential. Omitted portions are indicated by [*]. Execution Collaboration Agreement By and Between Rani Therapeutics, LLC and ProGen Co., Ltd. Dated June 17, 2024 CONFIDENTI
August 6, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC.
August 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2024 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (C
August 6, 2024	EX-99.1	Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update - Announced partnership with ProGen on development of RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity - - Phase 1 study for RT-114 expect Exhibit 99.1 Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update - Announced partnership with ProGen on development of RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity - - Phase 1 study for RT-114 expected to initiate in 2025 - - Completed equity offering with gross proceeds of approximately $10.0 million - - Presented clinical and precli
August 6, 2024	EX-10.2	Extension of Intellectual Property Agreement dated June 12, 2024 by and between Rani Therapeutics, LLC and Mir Imran.
August 6, 2024	EX-10.2	EX-10.2 Extension of Intellectual Property Agreement This Extension to Intellectual Property Agreement (the “Extension”) dated June 12, 2024 (the “Effective Date”) is made by and between Mir Imran (“Mir”) and Rani Therapeutics, LLC ("Rani").
July 23, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2024 Rani Therapeutics H UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2024 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Com
July 23, 2024	EX-10.1	Form of Securities Purchase Agreement, dated July 22, 2024. EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 22, 2024, between Rani Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the term
July 23, 2024	EX-4.1	Form of Series A Common Warrant EX-4.1 Exhibit 4.1 SERIES A COMMON STOCK PURCHASE WARRANT RANI THERAPEUTICS HOLDINGS, INC. Warrant Shares: Issuance Date: July 23, 2024 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after J
July 23, 2024	EX-4.3	Form of Pre-funded Warrant EX-4.3 Exhibit 4.3 PREFUNDED COMMON STOCK PURCHASE WARRANT RANI THERAPEUTICS HOLDINGS, INC. Warrant Shares: Issuance Date: July 23, 2024 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any ti
July 23, 2024	EX-4.2	Form of Series B Common Warrant EX-4.2 Exhibit 4.2 SERIES B COMMON STOCK PURCHASE WARRANT RANI THERAPEUTICS HOLDINGS, INC. Warrant Shares: Issuance Date: July 23, 2024 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after J
July 23, 2024	424B5	2,800,000 Shares of Class A Common Stock Pre-Funded Warrants to Purchase 446,753 Shares of Class A Common Stock Series A Common Warrants to Purchase 3,246,753 Shares of Class A Common Stock Series B Common Warrants to Purchase 3,246,753 Shares of Cla 424B5 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-266444 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 10, 2022) 2,800,000 Shares of Class A Common Stock Pre-Funded Warrants to Purchase 446,753 Shares of Class A Common Stock Series A Common Warrants to Purchase 3,246,753 Shares of Class A Common Stock Series B Common Warrants to Purchase 3,246,753 Shares of Class
July 12, 2024	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2024 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Com
June 24, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 Rani Therapeutics Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40672 86-3114789 (State or Other Jurisdiction of Incorporation) (Com
June 24, 2024	EX-99.1	This presentation and the accompanying oral statements contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933 and Section 21E of the Secu Rani Therapeutics and ProGen Collaboration June 24, 2024 Exhibit 99.1 This presentation and the accompanying oral statements contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act, including statements regarding collaboration between Rani T
May 30, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Comm
May 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 06, 2024 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Comm
May 6, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC.
May 6, 2024	EX-99.1	Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update - Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Initiation of Phase 2 clinical trial for RT-102 Exhibit 99.1 Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update - Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Initiation of Phase 2 clinical trial for RT-102 for the treatment of osteoporosis expected in 2024 – - RaniPill HC to be ready for potential Phase 1 clinical trials in the second half o
April 17, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi
April 17, 2024	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC.
April 17, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul
March 20, 2024	EX-FILING FEES	Filing Fee Table CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Rani Therapeutics Holdings, Inc.
March 20, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2024 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Co
March 20, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC.
March 20, 2024	EX-10.15	Amendment No. 2 to Service Agreement, dated March 15, 2024, by and between Rani Therapeutics, LLC and InCube Labs, LLC. Exhibit 10.15 Amendment No. 2 to Service Agreement This Amendment No. 2 to Service Agreement (“the “Amendment”) is made and entered into effective as of March 1, 2024 (the “Amendment Effective Date”) by and between InCube Labs, LLC, a Delaware limited liability company (“InCube”), and Rani Therapeutics, LLC, a California limited liability company (“Rani”), each a “Party” and collectively the “Part
March 20, 2024	EX-99.1	Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update - Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Announced Preclinical Pharmacodyn Exhibit 99.1 Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update - Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Announced Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist - - Cash runway extended into 2025 - - Conference call and webcast today
March 20, 2024	S-8	As filed with the U.S. Securities and Exchange Commission on March 20, 2024 As filed with the U.S. Securities and Exchange Commission on March 20, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 86-3114789 (State or other jurisdiction of incorporation or organiza
March 20, 2024	EX-21.1	Subsidiaries of the Registrant. Exhibit 21.1 List of subsidiaries of Rani Therapeutics Holdings, Inc. Name of Subsidiary Jurisdiction of Organization Rani Therapeutics, LLC California, United States of America
March 20, 2024	EX-10.17	Amendment No. 1 to RMS Service Agreement, dated March 15, 2024, by and between Rani Therapeutics, LLC and InCube Labs, LLC. Exhibit 10.17 Amendment No. 1 to RMS Service Agreement This Amendment No. 1 to Service Agreement (“the “Amendment”) is made and entered into as of the date of the last signature below (the “Amendment Effective Date”) by and between InCube Labs, LLC, a Delaware limited liability company (“InCube”), and Rani Therapeutics, LLC, a California limited liability company (“Rani”), each a “Party” and colle
February 5, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 05, 2024 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation)
February 5, 2024	EX-99.2	Our mission at Rani is to end painful injections for the millions of patients suffering from chronic diseases. Rani Therapeutics Corporate Presentation February 2024 NASDAQ: RANI Our mission at Rani is to end painful injections for the millions of patients suffering from chronic diseases.
February 5, 2024	EX-99.1	Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - RT-111 achieved high bioavailability in humans - - RT-111 was well-tolerated, with no serious adverse events - - Celltrion h Exhibit 99.1 Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - RT-111 achieved high bioavailability in humans - - RT-111 was well-tolerated, with no serious adverse events - - Celltrion has right of first negotiation to acquire worldwide rights to RT-111 following a Phase 1 clinical trial that meets its primary endpoints –
December 19, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2023 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation)
December 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation)
December 8, 2023	EX-99.1	Exhibit 99.1 — Joint Filing Agreement, dated December 8, 2023. EX-99.1 2 tm2332511d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 SCHEDULE 13D JOINT FILING AGREEMENT In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13D to which this Joint Filing Agreement is attached and have duly executed this Join
December 8, 2023	SC 13D/A	RANI / Rani Therapeutics Holdings Inc Class A / Quiroga Cortes Isidoro Alfonso - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Rani Therapeutics Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 753018 100 (CUSIP Number) Isidoro Alfonso Quiroga Cortés Aequanimitas Limited Partnership Avenida Presidente Riesco 5711
December 8, 2023	SC 13D/A	RANI / Rani Therapeutics Holdings Inc Class A / South Lake One, Llc - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Rani Therapeutics Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 753018 100 (CUSIP Number) Luis Felipe Correa González South Lake One LLC Avenida Presidente Riesco 5711 Oficina 1603, Las
December 8, 2023	EX-99.1	Exhibit 99.1 — Joint Filing Agreement, dated December 8, 2023. EX-99.1 2 tm2332511d2ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 SCHEDULE 13D JOINT FILING AGREEMENT In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13D to which this Joint Filing Agreement is attached and have duly executed this Join
November 8, 2023	EX-99.1	Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update - Cash runway extended into 2025 - - Announced strategic program prioritization, expansion of manufacturing and plans to streamline business operations - - Init Exhibit 99.1 Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update - Cash runway extended into 2025 - - Announced strategic program prioritization, expansion of manufacturing and plans to streamline business operations - - Initiated Phase 1 clinical trial of RT-111, a RaniPill GO containing ustekinumab biosimilar CT-P43, with topline results expected in 1Q 2024
November 8, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 08, 2023 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation)
November 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC.
November 8, 2023	EX-10.1	Standard Industrial/Commercial Multi-Tenant Lease – Net, by and between Rani Therapeutics, LLC and BKM South Bay 240, LLC, dated as of November 1, 2023 (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, filed with the SEC on November 8, 2023). Exhibit 10.1 Portions of this exhibit have been omitted as the Registrant has determined that (i) the omitted information is not material and (ii) the omitted material is of the type that the Registrant treats as private or confidential. Omitted portions are indicated by [*]. STANDARD INDUSTRIAL/COMMERCIAL MULTI-TENANT LEASE - NET SHORELINE BUSINESS CENTER FREMONT, CA LANDLORD: BKM SOUTH BAY 240,
November 1, 2023	EX-99.1	Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill® Technology Platform; Reports Preliminary Thi Exhibit 99.1 Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill® Technology Platform; Reports Preliminary Third Quarter 2023 Financial Results - Cash runway extended into 2025 - - Cash runway expected to extend beyond topline results from Phase 2
November 1, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 01, 2023 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation)
October 25, 2023	EX-99.1	The RaniPill® Capsule, Rani Therapeutics’ Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study - Daily administration for 60 days was well-tolerated with no treatment-related adverse events - - Preclinical dat Exhibit 99.1 The RaniPill® Capsule, Rani Therapeutics’ Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study - Daily administration for 60 days was well-tolerated with no treatment-related adverse events - - Preclinical data support the safety and tolerability of RaniPill® capsule for subsequent clinical studies - SAN JOSE, Calif., October 25, 2023 - Rani Th
October 25, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2023 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (
September 7, 2023	EX-99.2	Our mission at Rani is to end painful injections for the millions of patients suffering from chronic diseases. Rani Therapeutics Corporate Presentation September 2023 Our mission at Rani is to end painful injections for the millions of patients suffering from chronic diseases.
September 7, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 07, 2023 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation)
September 7, 2023	EX-99.1	- Two preclinical studies of RaniPill® HC achieved 18/20 successful drug delivery of orally administered teriparatide resulting in a cumulative 90% success rate - Rani will continue preclinical testing to confirm preliminary reliability rate and opti Exhibit 99.1 Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies - Two preclinical studies of RaniPill® HC achieved 18/20 successful drug delivery of orally administered teriparatide resulting in a cumulative 90% success rate - Rani will continue preclinical testing to confirm preliminary reliability rate and optimize device performance - Increased pay
August 11, 2023	EX-10.1	License and Supply Agreement by and between Rani Therapeutics, LLC and Celltrion, Inc. dated January 6, 2023 (incorporated by reference to Exhibit 10.27 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 22, 2023). Exhibit 10.1 Portions of this exhibit have been omitted as the Registrant has determined that (i) the omitted information is not material and (ii) the omitted material is of the type that the Registrant treats as private or confidential. Omitted portions are indicated by [*]. License and Supply Agreement By and Between Rani Therapeutics, LLC and Celltrion, Inc. Dated May 26, 2023 CONFIDENTIAL Lice
August 11, 2023	EX-99.1	Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update - Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Busin Exhibit 99.1 Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update - Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Business Officer - Presentation of three abstracts on RT-102 and RT-112 at the Endocrine Society Annual Conference and selection as winner of
August 11, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC.
August 11, 2023	EX-10.2	Employment Agreement, dated May 17, 2023, by and between Rani Therapeutics, LLC and Kate McKinley (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on form 10-Q for the quarter ended June 30, 2023, filed with the SEC on August 11, 2023). Exhibit 10.2 Portions of this exhibit have been omitted as the Registrant has determined that (i) the omitted information is not material and (ii) the omitted material is of the type that the Registrant treats as private or confidential. Omitted portions are indicated by []. Rani Therapeutics, LLC. Date Kate McKinley [] Re: Offer of Employment Dear Kate, Rani Therapeutics, LLC. (the “Company”) i
August 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (C
June 5, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 01, 2023 Rani Therapeutics Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40672 86-3114789 (State or Other Jurisdiction of Incorporation) (Com
May 30, 2023	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 Rani Therapeutics Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40672 86-3114789 (State or Other Jurisdiction of Incorporation) (Comm
May 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC.
May 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Comm
May 10, 2023	EX-99	Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update - Announced partnership with Celltrion on development of RT-111, a RaniPill GO capsule containing a biosimilar for the monoclonal antibody ustekinumab - - Recei Exhibit 99.1 Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update - Announced partnership with Celltrion on development of RT-111, a RaniPill GO capsule containing a biosimilar for the monoclonal antibody ustekinumab - - Received preliminary feedback from FDA on RT-102 development plans; 505(b)(2) pathway for RT-102 could be suitable - - Initiation of Phase 2 c
April 11, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul
April 11, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini
April 5, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 Rani Therapeutics Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40672 86-3114789 (State or Other Jurisdiction of Incorporation) (Co
March 22, 2023	S-8	As filed with the U.S. Securities and Exchange Commission on March 22, 2023 S-8 1 2023forms-8.htm S-8 As filed with the U.S. Securities and Exchange Commission on March 22, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 86-3114789 (State or other jurisdiction of
March 22, 2023	EX-10	License and Supply Agreement by and between Rani Therapeutics, LLC and Celltrion, Inc. dated January 6, 2023. Exhibit 10.27 Portions of this exhibit have been omitted as the Registrant has determined that (i) the omitted information is not material and (ii) the omitted material is of the type that the Registrant treats as private or confidential. Omitted portions are indicated by [*]. License and Supply Agreement By and Between Rani Therapeutics, LLC and Celltrion, Inc. Dated January 6, 2023 CONFIDENTIAL
March 22, 2023	EX-21	Subsidiaries of the Registrant. Exhibit 21.1 List of subsidiaries of Rani Therapeutics Holdings, Inc. Name of Subsidiary Jurisdiction of Organization Rani Therapeutics, LLC California, United States of America
March 22, 2023	EX-10	Amended and Restated Employment Agreement, dated August 31, 2022, by and between Rani Therapeutics, LLC and Talat Imran (incorporated by reference to Exhibit 10.19 to the Registrant’s Annual Report on form 10-K for the year ended December 31, 2022, filed with the SEC on March 22, 2023). Exhibit 10.19 August 31, 2022 Talat Imran VIA EMAIL Re: Amended and Restated Employment Agreement Dear Talat: You are currently employed by RANI MANAGEMENT SERVICES, INC. (“RMS”) under the terms of an employment agreement between you and RMS dated June 17, 2021 (the “ RMS Agreement”). Your employment is being transitioned from RMS to Rani Therapeutics, LLC (the “Company”) effective as of September
March 22, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Co
March 22, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC.
March 22, 2023	EX-FILING FEES	Filing Fee Table CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Rani Therapeutics Holdings, Inc.
March 22, 2023	EX-10	Amended and Restated Employment Agreement, dated August 31, 2022, by and between Rani Therapeutics, LLC and Svai Sanford (incorporated by reference to Exhibit 10.19 to the Registrant’s Annual Report on form 10-K for the year ended December 31, 2022, filed with the SEC on March 22, 2023). Exhibit 10.21 August 31, 2022 Svai Sanford VIA EMAIL Re: Amended and Restated Employment Agreement Dear Svai: You are currently employed by RANI MANAGEMENT SERVICES, INC. (“RMS”) under the terms of an employment agreement between you and RMS dated June 17, 2021 (the “ RMS Agreement”). Your employment is being transitioned from RMS to Rani Therapeutics, LLC (the “Company”) effective as of September
March 22, 2023	EX-10	Amended and Restated Employment Agreement, dated August 31, 2022, by and between Rani Therapeutics, LLC and Mir Hashim (incorporated by reference to Exhibit 10.19 to the Registrant’s Annual Report on form 10-K for the year ended December 31, 2022, filed with the SEC on March 22, 2023). Exhibit 10.20 August 31, 2022 Mir Hashim VIA EMAIL Re: Amended and Restated Employment Agreement Dear Mir Hashim: You are currently employed by RANI MANAGEMENT SERVICES, INC. (“RMS”) under the terms of an employment agreement between you and RMS dated June 17, 2021 (the “ RMS Agreement”). Your employment is being transitioned from RMS to Rani Therapeutics, LLC (the “Company”) effective as of Septe
March 22, 2023	EX-99	Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update - Anticipates initiating first Phase 2 clinical study in RT-102 in 2H of 2023 - - Announced topline results from the Phase 1 repeat-dose study of Exhibit 99.1 Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update - Anticipates initiating first Phase 2 clinical study in RT-102 in 2H of 2023 - - Announced topline results from the Phase 1 repeat-dose study of RT-102 for the treatment of osteoporosis - - Received preliminary feedback from FDA on RT-102 development plans; 505(b)(2) pathway for R
March 15, 2023	SC 13D/A	RANI / Rani Therapeutics Holdings Inc Class A / South Lake One, Llc - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Rani Therapeutics Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 753018 100 (CUSIP Number) Luis Felipe Correa González South Lake One LLC Avenida Presidente Riesco 5711 Oficina 1603, Las
March 15, 2023	EX-99.1	Exhibit 99.1 — Joint Filing Agreement, dated March 15, 2023. EXHIBIT 99.1 SCHEDULE 13D JOINT FILING AGREEMENT In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13D to which this Joint Filing Agreement is attached and have duly executed this Joint Filing Agreement as of March 15, 2023. Sout
January 9, 2023	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 06, 2023 Rani Therapeutics Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40672 86-3114789 (State or Other Jurisdiction of Incorporation) (
January 5, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 05, 2023 Rani Therapeutics Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40672 86-3114789 (State or Other Jurisdiction of Incorporation) (
January 5, 2023	EX-99.1	Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update - Preliminary feedback from FDA on RT-102 development plans; 505(b)(2) pathway for RT-102 could be suitable - - Multiple anticipated clinical milestones expec Exhibit 99.1 Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update - Preliminary feedback from FDA on RT-102 development plans; 505(b)(2) pathway for RT-102 could be suitable - - Multiple anticipated clinical milestones expected in 2023, including initiation of Phase 2 study of RT-102 in osteoporosis - SAN JOSE, Calif., January 5, 2023 - Rani Therapeutics Hold
December 30, 2022	8-K	Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2022 Rani Therapeutics Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40672 86-3114789 (State or Other Jurisdiction of Incorporation)
December 29, 2022	424B7	6,009,542 Shares of Class A Common Stock Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-268855 6,009,542 Shares of Class A Common Stock This prospectus relates to the resale from time to time of up to 6,009,542 shares of our Class A common stock, or the shares, including 533,740 shares issuable upon exchange of Class A common units of Rani Therapeutics, LLC, or LLC Interests, which are held by the selling stockho
December 27, 2022	CORRESP	RANI THERAPEUTICS HOLDINGS, INC. 2051 Ringwood Avenue San Jose, California 95131 RANI THERAPEUTICS HOLDINGS, INC. 2051 Ringwood Avenue San Jose, California 95131 December 27, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Christine Westbrook Re: Rani Therapeutics Holdings, Inc. Registration Statement on Form S-3 File No. 333-268855 Acceleration Request Requested Date: December 29,
December 22, 2022	LETTER	LETTER United States securities and exchange commission logo December 22, 2022 Talat Imran Chief Executive Officer Rani Therapeutics Holdings, Inc.
December 16, 2022	S-3	As filed with the U.S. Securities and Exchange Commission on December 16, 2022 Table of Contents As filed with the U.S. Securities and Exchange Commission on December 16, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RANI THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 86-3114789 (State or other jurisdiction of inco
December 16, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Rani Therapeutics Holdings, Inc.
December 6, 2022	EX-99.1	Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study - RT-102 achieved all of its endpoints in the repeat-dose Part 2 of the Phase 1 Study - - Repeat doses of RT-102 were generally well tolerated, with no serious adverse Exhibit 99.1 Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study - RT-102 achieved all of its endpoints in the repeat-dose Part 2 of the Phase 1 Study - - Repeat doses of RT-102 were generally well tolerated, with no serious adverse events - - RaniPill? GO delivered PTH to subjects with a 91% success rate and demonstrated high bioavailability - - Data from Part 1 and
December 6, 2022	EX-99.2	RT-102 Phase I Study Part 2: Repeat-Dose Update December 2022 RT-102 Phase I Study Part 2: Repeat-Dose Update December 2022 This presentation and the accompanying oral statements contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act.
December 6, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 06, 2022 Rani Therapeutics Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40672 86-3114789 (State or Other Jurisdiction of Incorporation)
November 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC.
November 10, 2022	EX-99.1	Rani Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update - RT-102 Phase 1 topline repeat-dose data anticipated in 4Q 2022 - - Announced preclinical development of RT-111, a RaniPill GO capsule containing ustekinuma Exhibit 99.1 Rani Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update - RT-102 Phase 1 topline repeat-dose data anticipated in 4Q 2022 - - Announced preclinical development of RT-111, a RaniPill GO capsule containing ustekinumab biosimilar for the potential treatment of psoriatic arthritis, ulcerative colitis, Crohn?s disease and psoriasis - - Announced RT-102 P
November 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Rani Therapeutics Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40672 86-3114789 (State or Other Jurisdiction of Incorporation)
October 24, 2022	EX-99.1	Rani Therapeutics Announces New RT-111 Development Program and Provides Corporate Update - Rani announces preclinical development of RT-111, a RaniPill GO capsule containing ustekinumab biosimilar for the potential treatment of psoriatic arthritis, u Exhibit 99.1 Rani Therapeutics Announces New RT-111 Development Program and Provides Corporate Update - Rani announces preclinical development of RT-111, a RaniPill GO capsule containing ustekinumab biosimilar for the potential treatment of psoriatic arthritis, ulcerative colitis, Crohn?s disease and psoriasis - - RT-102 Phase 1 repeat-dose topline data anticipated in 4Q 2022 - - Initiation of in
October 24, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2022 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (
August 25, 2022	EX-1.1	Controlled EquitySM Sales Agreement, dated August 24, 2022, by and among Rani Therapeutics Holdings, Inc., and Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC (incorporated by reference to Exhibit 1.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on August 25, 2022). EX-1.1 2 d385381dex11.htm EX-1.1 Exhibit 1.1 Rani Therapeutics Holdings, Inc. Shares of Class A Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement August 24, 2022 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 H.C. Wainwright & Co., LLC 430 Park Avenue, 3rd Floor New York, NY 10022 Ladies and Gentlemen: Rani Therapeutics Holdings, Inc., a Delaware c
August 25, 2022	424B5	Up to $150,000,000 Class A Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-266444 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 10, 2022) Up to $150,000,000 Class A Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement, dated August 25, 2022, or the Sales Agreement, with Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC, collectively, the Agents, relating to the sa
August 25, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2022 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (C
August 11, 2022	424B5	SUBJECT TO COMPLETION, AUGUST 10, 2022 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-266444 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to the securities offered hereby has been declared effective by the Securities and Exchange Commission under the Securities Act of 1933, as amended. This preliminary prospectus supplement and t
August 10, 2022	EX-99.1	Rani Therapeutics Reports Second Quarter 2022 Financial Results; Provides Corporate Update - Announced positive topline Phase 1 results of RT-102 for the treatment of osteoporosis - - Anticipate initiating an additional Phase 1 clinical trial in 2H 2 Exhibit 99.1 Rani Therapeutics Reports Second Quarter 2022 Financial Results; Provides Corporate Update - Announced positive topline Phase 1 results of RT-102 for the treatment of osteoporosis - - Anticipate initiating an additional Phase 1 clinical trial in 2H 2022 - - Capitalized to fund operations into mid-2024 - SAN JOSE, Calif., August 10, 2022 - Rani Therapeutics Holdings, Inc. (?Rani Therap
August 10, 2022	EX-10.1	Loan and Security Agreement, dated August 8, 2022, by and among the Registrant, its subsidiaries Rani Therapeutics, LLC and Rani Management Services, Inc., and Avenue Venture Opportunities Fund, L.P. (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on form 10-Q for the quarter ended June 30, 2022, filed with the SEC on August 10, 2022). Exhibit 10.1 LOAN AND SECURITY AGREEMENT Dated as of August 8, 2022 among RANI THERAPEUTICS, LLC, a California limited liability company, as ?Borrower?, RANI MANAGEMENT SERVICES, INC., a Delaware corporation, and as a guarantor RANI THERAPEUTICS HOLDINGS, INC., a Delaware corporation, as a guarantor (together with Rani Management Services, each, individually, a ?Guarantor,? and collectively, the ?
August 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC.
August 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 Rani Therapeutics Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40672 86-3114789 (State or Other Jurisdiction of Incorporation) (C
August 10, 2022	EX-10.3	Form of Warrant to purchase shares of Class A common stock of Registrant, issued to Avenue Venture Opportunities Fund, L.P. (incorporated by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on form 10-Q for the quarter ended June 30, 2022, filed with the SEC on August 10, 2022). Exhibit 10.3 THIS WARRANT AND THE UNDERLYING SECURITIES REPRESENTED BY THIS WARRANT HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE AND DISTRIBUTION THEREOF, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?) OR ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED, HYPOTHECATED OR OTHERW
August 10, 2022	CORRESP	RANI THERAPEUTICS HOLDINGS, INC. 2051 Ringwood Avenue San Jose, California 95131 RANI THERAPEUTICS HOLDINGS, INC. 2051 Ringwood Avenue San Jose, California 95131 August 10, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Abby Adams Alan Campbell Re: Rani Therapeutics Holdings, Inc. Registration Statement on Form S-3 File No. 333-266444 Acceleration Request Requested Date: August 10, 2022 Req
August 10, 2022	EX-10.2	Supplement to the Loan and Security Agreement, dated August 8, 2022, by and among the Registrant, its subsidiaries Rani Therapeutics, LLC and Rani Management Services, Inc., and Avenue Venture Opportunities Fund, L.P. (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on form 10-Q for the quarter ended June 30, 2022, filed with the SEC on August 10, 2022). Exhibit 10.2 SUPPLEMENT to the Loan and Security Agreement dated as of August 8, 2022 between Rani Therapeutics, LLC (?Borrower?) and Rani Management Services, Inc. , as a guarantor and Rani Therapeutics Holdings, Inc., as a guarantor (together with Rani Management Services, Inc., each, individually, a ?Guarantor,? and collectively, ?Guarantors?)) and Avenue Venture Opportunities Fund, L.P., a Del
August 10, 2022	EX-4.2	Exhibit 4.2 Exhibit 4.2 Description of Registrant?s Securities Registered Pursuant to Section 12 of the Securities and Exchange Act of 1934 The following is a description of the Class A common stock, par value $0.0001 per share (the ?Class A common stock?) of Rani Therapeutics Holdings, Inc. (?Rani?, the ?Company?, ?we?, ?our? or ?us?) which is our only class of security registered under Section 12 of the Sec
August 10, 2022	CORRESP	RANI THERAPEUTICS HOLDINGS, INC. 2051 Ringwood Avenue San Jose, California 95131 RANI THERAPEUTICS HOLDINGS, INC. 2051 Ringwood Avenue San Jose, California 95131 August 10, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Abby Adams Alan Campbell Re: Rani Therapeutics Holdings, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-266444 Ladies and Gentlemen: The under
August 9, 2022	CORRESP	RANI THERAPEUTICS HOLDINGS, INC. 2051 Ringwood Avenue San Jose, California 95131 RANI THERAPEUTICS HOLDINGS, INC. 2051 Ringwood Avenue San Jose, California 95131 August 9, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Abby Adams Alan Campbell Re: Rani Therapeutics Holdings, Inc. Registration Statement on Form S-3 File No. 333-266444 Acceleration Request Requested Date: August 11, 2022 Requ
August 8, 2022	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Co
August 3, 2022	LETTER	LETTER United States securities and exchange commission logo August 3, 2022 Svai Sanford Chief Financial Officer Rani Therapeutics Holdings, Inc.
August 1, 2022	EX-4.7	Form of Preferred Stock Warrant Agreement and Warrant Certificate Exhibit 4.7 RANI THERAPEUTICS HOLDINGS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF , 20 RANI THERAPEUTICS HOLDINGS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of , 20, between Rani Therapeutics Holdings, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national bank
August 1, 2022	S-3	As filed with the U.S. Securities and Exchange Commission on August 1, 2022 Table of Contents As filed with the U.S. Securities and Exchange Commission on August 1, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RANI THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 86-3114789 (State or other jurisdiction of incorpo
August 1, 2022	EX-4.8	Form of Debt Securities Warrant Agreement and Warrant Certificate Exhibit 4.8 RANI THERAPEUTICS HOLDINGS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF , 20 RANI THERAPEUTICS HOLDINGS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of , 20, between Rani Therapeutics Holdings, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national bank
August 1, 2022	EX-4.6	Form of Class A Common Stock Warrant Agreement and Warrant Certificate Exhibit 4.6 RANI THERAPEUTICS HOLDINGS, INC. AND , AS WARRANT AGENT FORM OF CLASS A COMMON STOCK WARRANT AGREEMENT DATED AS OF , 20 RANI THERAPEUTICS HOLDINGS, INC. FORM OF CLASS A COMMON STOCK WARRANT AGREEMENT THIS CLASS A COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of , 20, between Rani Therapeutics Holdings, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation]
August 1, 2022	EX-4.4	Form of Indenture Exhibit 4.4 RANI THERAPEUTICS HOLDINGS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of , 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1?DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2?ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate
August 1, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Rani Therapeutics Holdings, Inc.
May 26, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2022 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Comm
May 11, 2022	EX-10.2	Employment Agreement, dated April 12, 2022, by and between Rani Therapeutics, LLC and Eric Groen (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on form 10-Q for the quarter ended March 31, 2022, filed with the SEC on May 11, 2022). Exhibit 10.2 RANI THERAPEUTICS, LLC April 12, 2022 Eric Groen VIA EMAIL Re: Employment Agreement Dear Eric: You are currently employed by RANI MANAGEMENT SERVICES, INC. (?RMS?) under the terms of an offer letter between you and RMS dated July 29, 2021 (the ?Offer Letter?). Your employment is being transitioned to Rani Therapeutics, LLC (the ?Company?) and this employment agreement (the ?Agreement?
May 11, 2022	EX-99.1	Rani Therapeutics Reports First Quarter 2022 Financial Results; Provides Corporate Update - Initiated a Phase 1 clinical trial of RT-102 for the treatment of osteoporosis – - Unveiled the high-capacity RaniPill™ HC, capable of delivering payloads of EX-99.1 Exhibit 99.1 Rani Therapeutics Reports First Quarter 2022 Financial Results; Provides Corporate Update - Initiated a Phase 1 clinical trial of RT-102 for the treatment of osteoporosis – - Unveiled the high-capacity RaniPill™ HC, capable of delivering payloads of up to 20 mg – - Strengthened Board with the appointment of Lisa Rometty - SAN JOSE, Calif., May 11, 2022 — Rani Therapeutics Hold
May 11, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC.
May 11, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Comm
April 13, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini
April 13, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??) Filed by the Registrant ? ? ? ? ? Filed by a Party other than the Registrant ? ? ?? ? ? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission O
March 31, 2022	EX-10.14	Amendment No. 1 to Service Agreement, dated March 21, 2022, by and between Rani Therapeutics, LLC and InCube Labs, LLC (incorporated by reference to Exhibit 10.14 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed with the SEC on August 10, 2022). Exhibit 10.14 Amendment No. 1 to Service Agreement This Amendment No. 1 to Service Agreement (?the ?Amendment?) is made and entered into effective as of March 21, 2022 (the ?Amendment Effective Date?) by and between InCube Labs, LLC, a Delaware limited liability company (?InCube?), and Rani Therapeutics, LLC, a California limited liability company (?Rani?), each a ?Party? and collectively the ?Par
March 31, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC.
March 31, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Rani Therapeutics Holdings, Inc.
March 31, 2022	EX-10.3	Registration Rights Agreement, effective as of August 3, 2021 Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT BY AND AMONG RANI THERAPEUTICS HOLDINGS, INC. AND THE ?INVESTORS? as defined herein, Dated as of August 3, 2021 Table of Contents Page 1. DEFINITIONS 1 2. REGISTRATION RIGHTS 3 2.1 Demand Registration. 3 2.2 Shelf Take-Downs 4 2.3 Company Registration 5 2.4 Underwriting Requirements. 5 2.5 Obligations of the Company 6 2.6 Furnish Information 8 2.7 Expense
March 31, 2022	EX-10.4	Fifth Amended and Restated Limited Liability Company Agreement of Rani Therapeutics, LLC, effective as of August 3, 2021 (incorporated by reference to Exhibit 10.4 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 filed with the SEC on August 10, 2022). Exhibit 10.4 RANI THERAPEUTICS, LLC FIFTH AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT Dated as of August 3, 2021 THE UNITS REPRESENTED BY THIS FIFTH AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER ANY OTHER APPLICABLE SECURITIES LAWS. SUCH UNITS MAY NOT BE SOLD, ASSIGNED, PLEDGED OR
March 31, 2022	EX-10.8	Forms of Agreement under the Rani Therapeutics Holdings, Inc. 2021 Equity Incentive Plan. Exhibit 10.8 [FORM OF STANDARD OPTION GRANT PACKAGE] RANI THERAPEUTICS HOLDINGS, INC. 2021 EQUITY INCENTIVE PLAN STOCK OPTION GRANT NOTICE Rani Therapeutics Holdings, Inc. (the ?Company?), pursuant to its 2021 Equity Incentive Plan (as may be amended and/or restated as of the Date of Grant set forth below, the ?Plan?), has granted to Optionholder an option to purchase the number of shares of the C
March 31, 2022	S-8	As filed with the U.S. Securities and Exchange Commission on March 31, 2022 As filed with the U.S. Securities and Exchange Commission on March 31, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Rani Therapeutics Holdings, Inc. (Exact name of Registrant as specified in its charter) Delaware 86-3114789 (State or other jurisdiction of Incorporation or organiza
March 31, 2022	EX-4.2	Exhibit 4.2 Exhibit 4.2 Description of Registrant?s Securities Registered Pursuant to Section 12 of the Securities and Exchange Act of 1934 The following is a description of the Class A common stock, par value $0.0001 per share (the ?Class A common stock?) of Rani Therapeutics Holdings, Inc. (?Rani?, the ?Company?, ?we?, ?our? or ?us?) which is our only class of security registered under Section 12 of the Sec
March 31, 2022	EX-10.2	Class B Unit Exchange Agreement, effective as of August 3, 2021 (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 filed with the SEC on August 10, 2022). Exhibit 10.2 EXCHANGE AGREEMENT This Exchange Agreement (this ?Agreement?) is made and entered into as of August 3, 2021, by and between Rani Therapeutics Holdings, Inc., a Delaware corporation (the ?Company?) and the persons and entities (each, a ?Contributor? and collectively, the ?Contributors?) listed on Schedule I below. Each of the Contributors and the Company shall be known as a ?Party? her
March 31, 2022	EX-10.1	Tax Receivable Agreement, effective as of August 3, 2021 (incorporated by reference to Exhibit 10.1 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 31, 2022). Exhibit 10.1 TAX RECEIVABLE AGREEMENT between RANI THERAPEUTICS HOLDINGS, INC. and THE PERSONS NAMED HEREIN Dated as of August 3, 2021 Table of Contents Article I DEFINITIONS Section 1.1 Definitions Article II DETERMINATION OF CERTAIN REALIZED TAX BENEFIT Section 2.1 Basis Schedule Section 2.2 Tax Benefit Schedule Section 2.3 Procedures, Amendments Section 2.4 Basis Adjustments Article III TAX BEN
March 29, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2022 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Co
March 29, 2022	EX-99.1	Rani Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results; Provides Corporate Update - Initiated a Phase 1 clinical trial of RT-102 for the potential treatment of osteoporosis - - Unveiled the high-capacity RaniPill™ HC, capable o Exhibit 99.1 Rani Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results; Provides Corporate Update - Initiated a Phase 1 clinical trial of RT-102 for the potential treatment of osteoporosis - - Unveiled the high-capacity RaniPill? HC, capable of delivering payloads of up to 20 mg - - Strengthened Board with the appointments of Lyn Baranowski and Lisa Rometty ? - Conference call
March 23, 2022	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2022 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Co
February 23, 2022	EX-99.2	Forward Looking Statements This presentation and the accompanying oral statements contain forward-looking statements. Forward-looking statements are based on information available at the time those statements are made or on management's good faith be Rani Therapeutics Announcing RaniPill? HC February 2022 Exhibit 99.2 Forward Looking Statements This presentation and the accompanying oral statements contain forward-looking statements. Forward-looking statements are based on information available at the time those statements are made or on management's good faith beliefs and assumptions as of that time with respect to future events, and are subj
February 23, 2022	EX-99.1	Rani Therapeutics Unveils High-Capacity RaniPill™ Device For Oral Delivery of Biologics; Reports Preliminary 2021 Consolidated Financial Results - Preclinical data demonstrates new RaniPill™ HC (High Capacity) delivered 500%-plus higher payloads than Exhibit 99.1 Rani Therapeutics Unveils High-Capacity RaniPill? Device For Oral Delivery of Biologics; Reports Preliminary 2021 Consolidated Financial Results - Preclinical data demonstrates new RaniPill? HC (High Capacity) delivered 500%-plus higher payloads than current RaniPill? capsule - - Up to 20mg payload has the potential to unlock more than 50 additional biologics for internal development
February 23, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation)
February 14, 2022	EX-99.1	JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be
February 14, 2022	SC 13G	RANI / Rani Therapeutics Holdings, Inc. Class A / InCube Ventures II, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Rani Therapeutics Holdings, Inc. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 753018100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box
February 1, 2022	SC 13D	RANI / Rani Therapeutics Holdings, Inc. Class A / Quiroga Cortes Isidoro Alfonso - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Rani Therapeutics Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 753018 100 (CUSIP Number) Isidoro Alfonso Quiroga Cortés Aequanimitas Limited Partnership Avenida Presidente Riesco 5711 Ofi
February 1, 2022	SC 13D/A	RANI / Rani Therapeutics Holdings, Inc. Class A / South Lake One, Llc - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Rani Therapeutics Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 753018 100 (CUSIP Number) Luis Felipe Correa González South Lake One LLC Avenida Presidente Riesco 5711 Oficina 1603, Las
February 1, 2022	EX-99.1	Power of Attorney granted by Isidoro Quiroga Moreno, dated October 20, 2021. EX-99.1 2 tm225035d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 GENERAL POWER OF ATTORNEY ISIDORO ERNESTO QUIROGA MORENO, Chilean, married, businessman, national identity card number 6.397.675-K, domiciled on the First and Second Floor 28-29 Hans Place, London, SW1X OJY, hereinafter the “Principal,” hereby grants a full power of attorney, as broad as corresponds by law, to: a/ Luis Felipe Correa González
February 1, 2022	EX-99.1	SCHEDULE 13D JOINT FILING AGREEMENT EXHIBIT 99.1 SCHEDULE 13D JOINT FILING AGREEMENT In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13D to which this Joint Filing Agreement is attached and have duly executed this Joint Filing Agreement as of February 1, 2022. Ae
February 1, 2022	EX-99.2	Joint Filing Agreement EXHIBIT 99.2 SCHEDULE 13D JOINT FILING AGREEMENT In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13D to which this Joint Filing Agreement is attached and have duly executed this Joint Filing Agreement as of February 1, 2022. Is
January 5, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2022 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (C
November 16, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation)
November 16, 2021	EX-99.1	Rani Therapeutics Reports Third Quarter 2021 Financial Results, Provides Corporate Update Exhibit 99.1 Rani Therapeutics Reports Third Quarter 2021 Financial Results, Provides Corporate Update SAN JOSE, Calif., November 15, 2021?Rani Therapeutics Holdings, Inc. (?Rani Therapeutics? or ?Rani?) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today reported financial results for the quarter ended September 30, 2021, and provided a corpor
November 16, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC.
November 16, 2021	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 Commission File Number: 001-40672 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 Commission File Number: 001-40672 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR ? For the Transition Period Ended: Read Instruction (on back page) Before Preparing Form.

RANI / Rani Therapeutics Holdings, Inc. - Arquivamentos da SEC, Relatório Anual, Declaração de Procuração

Estatísticas Básicas

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?